Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen
出版年份 2013 全文链接
标题
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen
作者
关键词
<em class=EmphasisTypeItalic >PIK3CA</em> mutations, Breast cancer, First-line endocrine therapy, Prognosis
出版物
BREAST CANCER RESEARCH AND TREATMENT
Volume 139, Issue 1, Pages 39-49
出版商
Springer Nature
发表日期
2013-04-16
DOI
10.1007/s10549-013-2529-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients
- (2012) Bichlien Nguyen et al. ANNALS OF SURGICAL ONCOLOGY
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
- (2012) F. Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
- (2012) Karin Beelen et al. Nature Reviews Clinical Oncology
- The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer
- (2012) Amaury G. Dumont et al. Chinese Journal of Cancer
- Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes
- (2011) Sandrine Boyault et al. BREAST CANCER RESEARCH AND TREATMENT
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- TheCYP2C19*2genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
- (2011) Ron HN van Schaik et al. PHARMACOGENOMICS
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
- (2010) Ruth E. Board et al. BREAST CANCER RESEARCH AND TREATMENT
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
- (2010) J. Dupont Jensen et al. CLINICAL CANCER RESEARCH
- PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001
- (2010) Morassa Mohseni et al. JOURNAL OF CLINICAL INVESTIGATION
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
- (2010) Bhuvanesh Dave et al. JOURNAL OF CLINICAL ONCOLOGY
- Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
- (2010) Irene Lurkin et al. PLoS One
- FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
- (2010) Lucie C. Kompier et al. PLoS One
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
- (2010) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma
- (2009) Jennifer Dunlap et al. BREAST CANCER RESEARCH AND TREATMENT
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
- (2009) Krishna M. Vasudevan et al. CANCER CELL
- Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
- (2009) T. W. Miller et al. CANCER RESEARCH
- Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
- (2009) P. Roepman et al. CLINICAL CANCER RESEARCH
- PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
- (2009) K. Kalinsky et al. CLINICAL CANCER RESEARCH
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients
- (2008) Yuen-Liang Lai et al. ANNALS OF SURGICAL ONCOLOGY
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started